Antibody-drug conjugates (ADCs) represent an emerging class of therapeutics across solid tumor oncology and are already positioned as a cornerstone therapy for patients with urothelial carcinoma (UC).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback